STOCK TITAN

DBV Technologies - DBVT STOCK NEWS

Welcome to our dedicated news page for DBV Technologies (Ticker: DBVT), a resource for investors and traders seeking the latest updates and insights on DBV Technologies.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect DBV Technologies's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of DBV Technologies's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.12%
Tags
clinical trial
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.23%
Tags
conferences
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.77%
Tags
earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.44%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.57%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.62%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.57%
Tags
clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.11%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.11%
Tags
earnings
DBV Technologies

Nasdaq:DBVT

DBVT Rankings

DBVT Stock Data

144.14M
39.34M
19.63%
0.28%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
France
Montrouge

About DBVT

dbv technologies is opening up a decisive new approach to the treatment of allergy – a major public health issue that is constantly increasing in prevalence. food allergies represent a true handicap in everyday life for millions of people and thus constitute a major unmet medical need. dbv technologies (incorporated in 2002) has developed a unique, proprietary, worldwide-patented technology for administering an allergen to intact skin and avoiding massive transfer to the blood. the viaskin® technology combines efficacy and safety as part of a treatment that seeks to improve the patient's tolerability of peanut and thus considerably lower the risk of a systemic, allergic reaction in the event of accidental exposure to the allergen. the product's clinically proven safety of use enables the application of effective desensitization techniques (the efficacy of which is acknowledged worldwide) in the most severe forms of the allergy. dbv technologies is focusing on food allergies (milk and